Acquiring Company
BioGen
Acquired Company
Alcyone Therapeutics
CambridgeLowellBiotechnologyHealth CareBiotechnology ResearchHealth CareTherapeuticsDescription
Biogen Inc. has successfully completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company specializing in CNS therapy delivery. This acquisition aims to enhance Biogen's portfolio and expertise in innovative drug delivery solutions. The collaboration plans to progress the development of Alcyone's ThecaFlex DRx™ system, offering a novel approach to administering therapies for neurological conditions.
Quick answer
BioGen is acquiring Alcyone Therapeutics, announced November 14, 2025. BioGen is based in Cambridge, Massachusetts, United States.
- How much did BioGen pay for Alcyone Therapeutics?
- The deal value was not disclosed.
- What does BioGen do?
- BioGen is a biotechnology company specializing in the development of therapies for neurological diseases.
- Where are BioGen and Alcyone Therapeutics based?
- BioGen is based in Cambridge, Massachusetts, United States. Alcyone Therapeutics is based in Lowell, Massachusetts, United States.
- Who are the decision-makers at BioGen?
- Fundz holds 1 contact at BioGen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology Research and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- BioNTech completes acquisition of CureVac (December 20, 2025)
- BioMarin to acquire Amicus for $4.8 billion, $4.8B (December 19, 2025)
- Day One to acquire Mersana for $130 million, $130M (November 30, 2025)
- Galecto, Inc. Acquires Damora Therapeutics, Inc. (November 10, 2025)
- XOMA Royalty acquires LAVA Therapeutics N.V. (November 21, 2025)
- ClearPoint Neuro acquires IRRAS for $5 million, $5M (November 20, 2025)
Who to call at BioGen, and when
When BioGen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioGen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioGen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioGen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioGen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Alcyone Therapeutics?
Alcyone Therapeutics was acquired by BioGen, based in Cambridge. The deal was reported on November 14, 2025. BioGen is a biotechnology company specializing in the development of therapies for neurological diseases. It has pioneered innovations in treatment for various neurodegenerative conditions. BioGen is publicly traded (BIIB) and operates in Biotechnology.
When did BioGen acquire Alcyone Therapeutics?
BioGen's acquisition of Alcyone Therapeutics was reported on November 14, 2025. Biogen Inc. has successfully completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company specializing in CNS therapy delivery. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Alcyone Therapeutics do?
Alcyone Therapeutics is a clinical-stage biotechnology company pioneering next-generation precision genetic therapies for complex neurological conditions. It is privately held, operating in Health Care, and is based in Lowell.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.